Introduction
============

Angiogenesis in physiology and pathology
----------------------------------------

Angiogenesis or neovascularization -- the growth of new capillaries from pre-existing microvasculature \[[@b1]\]-- sustains tissue growth and repair in normal adult physiology: during wound healing, ovarian and endometrial cycling, as well as muscle adaptations to exercise training \[[@b2], [@b3]\]. Angiogenesis can occur through distinct pathways: elevated microvascular shear stress triggers *splitting angiogenesis*, the intraluminal splitting of a microvessel longitudinally into two vessels; while tissue hypoxia stimulates *sprouting angiogenesis*, the abluminal budding of a new capillary sprout laterally from an existing microvessel \[[@b3], [@b4]\]. Related to splitting angiogenesis is *intussusceptive angiogenesis* caused by the formation of transvascular tissue pillars dividing the existing microvessel \[[@b5]\]. Tight regulation of the dynamic equilibrium between pro-angiogenic (angiogenic) and anti-angiogenic (angiostatic) processes is critical to health, as an imbalance in either direction contributes to a myriad of pathological conditions. Diseases characterized by excessive and abnormally coordinated angiogenesis include cancer, retinopathy, choroidal neovascularization, arthritis, atherosclerosis, psoriasis and endometriosis, whereas heart, brain and peripheral ischemia, as well as diabetes, hypertension, pre-eclampsia and nephropathy are characterized by insufficient angiogenesis \[[@b6]\].

Angiogenesis in current medicine
--------------------------------

The wide range of 'angiogenesis-dependent diseases' offers the promise of angiogenesis as a therapeutic target. In clinical trials designed to manipulate the 'angiogenic balance'*in vivo* as a therapeutic strategy \[[@b2], [@b7], [@b8]\], anti-angiogenic therapy seeks to down-regulate angiogenesis stimulators and/or up-regulate angiogenesis inhibitors; while pro-angiogenic therapy aims to up-regulate angiogenesis stimulators and/or down-regulate angiogenesis inhibitors.

At the molecular level, common targets of these therapeutic angiogenesis inhibitors and stimulators are the ligands and receptors of the vascular endothelial growth factor (VEGF) system, in which the ligand VEGF transduces pro-angiogenic signals through receptor tyrosine kinases such as VEGFR2 (VEGF receptor-2), while the soluble receptor sVEGFR1 is inhibitory to angiogenic signalling, partially through VEGF sequestration.

In the category of anti-angiogenic therapy, a prime research focus has been on the development of angiogenesis inhibitors as anti-cancer drugs, including the FDA-approved bevacizumab (a humanized monoclonal antibody against VEGF), sorafenib and sunitinib (receptor tyrosine kinase inhibitors) \[[@b9]\]; many others still in clinical trials, including endostatin (a broad-spectrum endothelial cell inhibitor) \[[@b10], [@b11]\]; and recently, the gene/protein delivery of sVEGFR1 in pre-clinical studies \[[@b12]--[@b21]\]. Recent studies have demonstrated synergistic benefits of combining specific anti-angiogenic therapy with conventional chemotherapy (the use of cytotoxic agents in targeting proliferating tumour cells) \[[@b9], [@b22]\].

In the category of pro-angiogenic therapy, also known as *therapeutic angiogenesis*, almost a dozen clinical trials have been conducted for the gene and protein delivery of VEGF to treat coronary artery disease (CAD) and peripheral arterial disease (PAD), which are atherosclerotic vascular diseases that result in muscle ischemia \[[@b23], [@b24]\]. These randomized, controlled clinical trials have not been able to reproduce the efficacy consistently observed in pre-clinical animal studies \[[@b23], [@b24]\]. One proposed reason is that patients with these vascular diseases may also suffer from ligand insensitivity due to impaired receptor signalling or increased expression of antagonists (*e.g.* sVEGFR1), rather than simply a deficiency in angiogenic growth factor expression \[[@b23], [@b25]\]. Another proposed reason is that the pharmacokinetics of VEGF administration are not optimal for localizing pro-angiogenic responses within ischemic tissue, and that systemic elevation of angiogenic growth factors in blood may contribute to: (*i*) side effects such as transient tissue oedema (VEGF strongly induces vascular permeability) and (*ii*) the counter-effect of further promoting angiogenesis at the vasa vasorum feeding the growth of primary atherosclerotic plaques \[[@b23], [@b26], [@b27]\].

VEGF ligand and receptor system: where does sVEGFR1 fit?
--------------------------------------------------------

### Ligands: the human VEGF family

Human VEGF is a family of related proteins: VEGF-A, VEGF-B and PlGF (placental growth factor) primarily involved in the growth of blood vessels \[[@b28], [@b29]\]; and VEGF-C and VEGF-D primarily involved in lymphangiogenesis (growth of lymphatic vessels) \[[@b30]\]. VEGF is secreted in cysteine-linked dimeric form \[[@b28]\], primarily as anti-parallel homodimers (VEGF/VEGF) but possibly as heterodimers (*e.g.* PlGF/VEGF) \[[@b31]\].

In most adult tissues, VEGF-A (also commonly referred to as simply VEGF) is secreted primarily from mesenchymal, stromal and epithelial sources (*e.g.* myocytes in muscles; platelets in blood; tumour cells and stromal cells in tumours) to act on endothelial cells in a paracrine fashion \[[@b9], [@b32], [@b33]\]. The biological roles traditionally attributed to VEGF have thus been mostly vascular: promoting the survival, migration, and proliferation of endothelial cells and increasing vascular permeability of vessels \[[@b28], [@b33]\]. Both the sprouting and splitting modes of angiogenesis are dependent on VEGF-A \[[@b3], [@b4]\]. However, there is a growing list of non-vascular roles for VEGF (*e.g.* recruitment of inflammatory cells and endothelial precursor cells \[[@b33]\]; neuroprotection in central nervous system and retina \[[@b34]\]), as well as evidence for autocrine and intracrine production and function of VEGF (*e.g.* in endothelial, tumour and haematopoietic stem cells \[[@b9], [@b35]\]).

Among the many splice variants of human VEGF-A ([Fig. 1](#fig01){ref-type="fig"}) are: the pro-angiogenic isoforms VEGF~121~, VEGF~145~, VEGF~165~, VEGF~183~, VEGF~189~ and VEGF~206~; and their anti-angiogenic counterparts VEGF~xxx~b most prevalent in non-angiogenic tissues, *e.g.* colon and skin \[[@b36], [@b37]\]. The VEGF-A exons conferring isoform-specific affinities with receptors and co-receptors are illustrated in [Fig. 1](#fig01){ref-type="fig"}. The relatively high endogenous expression of VEGF~121~ and VEGF~165~ have led to their testing as therapeutic agents in pro-angiogenic treatment for ischemic pathologies such as PAD and CAD \[[@b23], [@b24]\].

![Alternatively spliced mRNA isoforms of VEGF family members VEGF-A and PlGF. The exons encoding for protein domains that are generally responsible for interaction with receptors (sVEGR1, VEGFR1, VEGFR2), co-receptors (NRPs) and matrix proteins (HSPGs) are demarcated with colour-coded arrows. Once secreted into the extracellular space, the VEGF~121~ protein is generally considered a freely diffusible isoform, while VEGF~165~ and VEGF~189~ are sequestered in significant quantities at interstitial proteoglycans through its heparin-binding domain on exons 6 and 7 (see below). VEGF-A binding to cell surface receptors through their common exons 1--5 can lead to pro- or anti-angiogenic signal transduction depending on activated receptor type (see [Fig. 3](#fig03){ref-type="fig"}). Traditionally, VEGF-A was thought to bind NRP1 soley through exon 7 (contained in the higher molecular-weight isoforms, VEGF~\>121~); recently, NRP binding through exon 8 (contained in all VEGF-A isoforms) has also been suggested \[[@b37]\]. PlGF is (s)VEGFR1-specific and does not signal through VEGFR2. Similar to VEGF-A, there are freely diffusible isoforms (PlGF-1 and -3) and isoforms with a heparin-binding exon 6 that allows sequestration at interstitial matrix sites (PlGF-2 and -4). The molecular icons shown to the left of VEGF~121~, VEGF~165~, PlGF1 and PlGF2 are used in subsequent figures.](jcmm0014-0528-f1){#fig01}

PlGF is also an important ligand for VEGFR1 and sVEGFR1, but not for VEGFR2 \[[@b28]\] ([Fig. 1](#fig01){ref-type="fig"}). The pathological disorder of pre-eclampsia sheds light on the critical interplay between PlGF and sVEGFR1. There is increasing evidence that hypoxia-induced placental production of sVEGFR1 plays a causal role in the pathogenesis of pre-eclampsia, a pregnancy disorder in which placental hypoxia and maternal endothelial dysfunction lead to multi-organ disease including hypertension and proteinuria \[[@b38]--[@b41]\]. In pre-eclampsia, increased circulating sVEGFR1 has been correlated with reduced free PlGF and reduced free VEGF in the blood compared to normal pregnancies \[[@b41]--[@b45]\].

### Membrane-bound signalling receptors: VEGFRs

Full-length VEGF receptors-1, -2 and -3 (VEGFR1, VEGFR2, VEGFR3) are membrane-tethered receptor tyrosine kinases that are activated through homo/hetero-dimerization and ligand-induced trans-phosphorylation of intracellular tyrosine residues \[[@b29]\]. VEGFR3, as the receptor for VEGF-C and VEGF-D, largely mediates lymphangiogenic signalling \[[@b46]\] and will not be discussed here. VEGFR1 and VEGFR2 are expressed primarily on endothelial cells and they predominantly partake in the regulation of blood vessel angiogenesis (regulation of capillary sprouting and splitting), blood vessel maintenance, endothelial cell migration, endothelial cell proliferation, blood vessel permeability and dilation of blood vessels \[[@b28], [@b33]\]; but their expression on non-vascular cells (*e.g.* haematopoietic stem cells and megakaryocytes, the precursors of platelets; monocytic and dendritic immune cells; neural cells) further supports the aforementioned non-vascular biological roles of VEGF in normal adult physiology \[[@b34]\].

VEGFR2 (also known as KDR in human beings and Flk-1 in mice) is considered the predominant effector of pro-angiogenic signalling in sprouting angiogenesis and endothelial cell survival \[[@b9]\]. VEGFR2 is specific to VEGF-A and does not bind PlGF \[[@b29]\] ([Fig. 1](#fig01){ref-type="fig"}).

On the other hand, VEGFR1 (also known as FLT-1 in human beings and Flt-1 in mice) binds both VEGF-A and PlGF \[[@b29]\] ([Fig. 1](#fig01){ref-type="fig"}), and can mediate either anti- or pro-angiogenic signalling depending on the activating ligand type \[[@b46]\]. VEGF-A binding to VEGFR1 is generally considered anti-angiogenic -- possibly due to sequestration of VEGF-A which lowers its availability for VEGFR2 activation, although direct intracellular signal transduction has not been ruled out \[[@b31], [@b46]--[@b48]\]. In contrast, PlGF binding to VEGFR1 leads to pro-angiogenic signalling -- either by direct intracellular activation of VEGFR1, by displacing VEGF-A which then binds and signals through VEGFR2, or by intracellular 'crosstalk' (inter-molecular transphosphorylation) between the PlGF-activated VEGFR1 and VEGF-activated VEGFR2 \[[@b31], [@b46]\].

To our knowledge, the *in vivo* proportions of receptor homodimers (*e.g.* VEGFR1/VEGFR1, VEGFR2/VEGFR2) *versus* heterodimers (*e.g.* VEGFR1/VEGFR2) have not been experimentally quantified. A computational study -- through mathematical modelling of various ligand-induced and ligand-independent VEGFR dimerization schemes -- has predicted that heterodimers may constitute 10--50% of actively signalling VEGF receptor complexes \[[@b48]\]. Receptor heterodimers may be activated by ligand homodimers (*e.g.* VEGF/VEGF \[[@b49]\]) or heterodimers (*e.g.* VEGF/PlGF \[[@b31]\]), and may transduce completely different signals (in sign or magnitude) compared to the homodimerized forms of its constituents \[[@b48]\].

### Non-signalling co-receptors and matrix proteins: HSPGs and NRPs

A variety of heparin-related proteins in the extracellular space have binding sites for the longer VEGF-A isoforms (VEGF~\>121~). A significant source of interstitial VEGF-binding sites are the 'SAS (N-sulphated/acetylated/sulphated) domains'\[[@b50]\] on glycosaminoglycan chains of heparan sulphate proteoglycans (HSPGs) such as perlecan, agrin and collagen XVIII \[[@b51], [@b52]\]. A comparatively less prevalent diffusible source is the heparin-II binding domains of soluble fibronectins \[[@b53]\]. There are also HSPGs tethered on cell surfaces that facilitate surface VEGF-VEGFR binding and modulate the internalization rates of resultant complexes \[[@b46]\].

The cell-surface glycoproteins neuropilin-1 (NRP1) and neuropilin-2 (NRP2) were discovered originally as neuronal axon guidance receptors, but later found to be functionally significant in vascular formation as well \[[@b28], [@b54]\]. NRP1 directly binds VEGF~165~, PlGF-2 and possibly to a weaker degree, VEGF~121~\[[@b55]\]; NRP2 additionally binds VEGF~145~ and VEGF-C, suggesting a functional bias for lymphangiogenesis \[[@b28], [@b46], [@b54]\].

NRPs are typically considered non-signalling receptors, but they serve as co-receptors for the VEGF family *via* complex formation with VEGFRs \[[@b46]\]. The presence of NRP1 exerts an overall pro-angiogenic effect on VEGF-signalling through two synergistic mechanisms \[[@b56]\]. Firstly, NRP1 can couple with VEGFR1 directly, with the resultant unligated complex NRP1-VEGFR1 permissive to subsequent binding by VEGF~121~ but not VEGF~165~\[[@b56]\]. In other words, NRP1 makes VEGFR1 less available for VEGF~165~ activation, thereby decreasing inhibitory or modulatory VEGFR1 signalling through the VEGF~165~ isoform \[[@b56]\]. Secondly, NRP1 cannot couple VEGFR2 directly, but can still form a VEGFR2-VEGF~165~-NRP1 complex through non-overlapping VEGFR2-binding and NRP1-binding sites on the VEGF~165~'bridge'\[[@b56]\]. In this manner, NRP1 augments VEGF~165~ activation of VEGFR2 by both stabilizing VEGF~165~-VEGFR2 complexes and presenting NRP1-bound VEGF~165~ to VEGFR2, thus increasing pro-angiogenic VEGFR2 signalling through the VEGF~165~ isoform \[[@b56], [@b57]\]. An illustration and detailed discussion can be found in Mac Gabhann *et al.*\[[@b56]\].

### Soluble receptors

Soluble VEGF receptor-1 (sVEGFR1) was initially cloned in 1993 \[[@b58]\] and is a truncated ∼110 kDa splice variant of the 180 kDa membrane-spanning VEGFR1 \[[@b28], [@b45], [@b59]\]. The natural occurrence of sVEGFR1 -- derived predominantly from alternative splicing \[[@b58]\], but possibly also from proteolytic cleavage of full-length VEGFR1 \[[@b16]\]-- has been well documented, first in the pathophysiology of pre-eclampsia, and more recently also in numerous other physiological conditions \[[@b40], [@b41]\]. The molecular mechanisms of sVEGFR1's purported anti-angiogenic effects have not been well elucidated, but are believed to include: (1) sequestration of VEGF ligands, much like VEGFR1 does, and effectively reducing VEGF-mediated activation of pro-angiogenic receptors and (2) heterodimerization with full-length VEGFR monomers to render the receptor dimer inactive, because sVEGFR1 lacks the intracellular tyrosine kinase domain needed to transphosphorylate its full-length partner \[[@b45], [@b60]\]. As discussed in detail below, there is growing interest in biomedical research to explore sVEGFR1 as a disease marker \[[@b42], [@b61]--[@b63]\] and a therapeutic vector for angiogenesis inhibition \[[@b12], [@b18], [@b64]\].

There is emerging evidence for soluble forms of other receptors as well. Soluble VEGFR2 is present in significant quantities in healthy human plasma (7--8 ng/ml) \[[@b65]\] and is up-regulated in acute myeloid leukaemia \[[@b66]\]. Soluble NRP1, a VEGF~165~-specific antagonist, has been documented in the kidney in human beings \[[@b67], [@b68]\]. However, this mini review will focus on sVEGFR1.

Molecular biology of sVEGFR1
============================

The molecular weight of sVEGFR1 appears to be both glycosylation- and species-dependent. The size of sVEGFR1 has been documented as 60 kDa in mice \[[@b69]\], 85--90 kDa when recombinantly expressed in transfected insect cells (Sf9) \[[@b58]\], 110 kDa when expressed by human umbilical vein endothelial cells (HUVEC) and primary human dermal microvascular endothelial cells (MVEC) \[[@b59], [@b60]\], 120--130 kDa when produced by melanoma cells (COLO-800) \[[@b59]\], 116 kDa in human placental tissue lysates \[[@b45]\] and 150 kDa (that deglycosylates to 115 kDa) in serum and amniotic fluid samples from pregnant women \[[@b70]\]. Of note, however, it is possible that these marked differences in molecular weight, particularly *in vivo*, may reflect proteolyic processing of either full-length VEGFR1 or sVEGFR1 (described further below), as there is no detectable difference in molecular weight when either mouse or human sVEGFR1 cDNA is expressed in various mammalian cells (CDK, BHA, unpublished observations).

sVEGFR1 has been found to bind VEGF in monomeric, dimeric, even multimeric forms *in vitro* and *ex vivo*, forming complexes weighing 115--145 kDa \[[@b58], [@b59]\], 220--230 kDa \[[@b58], [@b59]\] and 600--700 kDa \[[@b70]\], respectively, which suggests ligand-induced di/multi-merization, but the relative proportions of these various forms *in vivo* have yet to be quantified.

While sVEGFR1 has traditionally been considered a single protein, emerging evidence point to a family of at least four alternatively spliced soluble VEGFR1 proteins \[[@b71]\]. The mRNA transcripts of all known sVEGFR1 variants are common through to exon 13; thus invariably, the sVEGFR1 protein retains the first six N-terminal immunoglobulin-like (Ig)-like extracellular motifs of VEGFR1, but lacks VEGFR1's seventh Ig-like domain as well as the membrane-anchoring region, regulatory (repressive) juxtamembrane domain and intracellular signalling tyrosine kinase domains \[[@b46], [@b58]\] ([Fig. 2](#fig02){ref-type="fig"}). The four known splice variants differ in their unique C-terminus as follows: (*i*) sFlt1_v1, originally discovered in 1993 by Kendall *et al*. \[[@b58]\] and traditionally referred to as 'sFlt-1', ends with an extension of exon 13; (*ii*) sFlt1_v2, identified by Thomas *et al*. as 'sFlt1-e15a' in 2007 \[[@b72]\] and Sela *et al*. as 'sFlt1--14' in 2008 \[[@b73]\], includes exon 14 and terminates with exon 15a sequences \[[@b73]\]; (*iii*) sFlt1_v3, identified in 2009 by Heydarian *et al*. \[[@b71]\], includes exon 14 and terminates with exon 15b and (*iv*) sFlt1_v4, also identified by Heydarian *et al*. in 2009 \[[@b71]\], includes exon 14 and terminates with an extension of exon 14. A detailed illustration of the structural differences between the 3′ terminal exons of sVEGFR1 splice variants can be found in Heydarian *et al*. \[[@b71]\] Evidently, the splice variants of sVEGFR1 are subject to species-specific and cell-type-specific differential regulation at both transcriptional and translational levels, although the molecular details of which are still unclear \[[@b71], [@b73]\]. Hypoxia has been observed to up-regulate sVEGFR1 expression *via* HIF1-α, a process that likely contributes to the pathogenesis of pre-eclampsia \[[@b74]\].

![Protein structures of soluble *versus* membrane-anchored VEGFR1. sVEGFR1 (110 kDa) is a soluble, truncated, alternatively spliced version of the full-length VEGFR1 protein (180 kDa) and has been found to bind VEGF in both dimeric and monomeric forms *in vitro*. Both share the first six immunoglobulin-like loops on their N-terminus; thus sVEGFR1 theoretically inherits VEGFR1's affinity for ligands (*e.g.* VEGF) and accessory molecules (*e.g.* interstitial heparan sulphate proteoglycans and neuropilins), as well as VEGFR1's dimerization properties. sVEGFR1 has a unique C-terminus and lacks the transmembrane region and intracellular tyrosine kinase signalling domains of VEGFR1.](jcmm0014-0528-f2){#fig02}

Furthermore, an *in vitro* study documented in microvascular endothelial cells a γ-secretase-dependent intramembrane proteolysis of membrane-bound VEGFR1 and the intracellular release of an 80 kDa C-terminal fragment \[[@b16]\]. This finding prompted speculations of extracellular shedding of the remnant ∼100 kDa N-terminal fragment, which may contribute to the interstitial/plasma population of sVEGFR1 as a proteolytically cleaved counterpart to its alternatively spliced forms. More recently, ligand-induced proteolytic cleavage and ectodomain shedding of VEGFR1 was further documented in human leukaemia cancer cells \[[@b75]\]. Hereafter in this review, 'sVEGFR1' will refer to the entire family of alternatively spliced and cleaved variants of sVEGFR1.

Theoretically, the molecular interactions of sVEGFR1 with VEGF family ligands are expected to be similar to those of VEGFR1 due to preservation of the first six Ig-like domains: the first three domains, especially the second and third, are involved in the binding of competing ligand family members, including VEGF-A, VEGF-B and PlGF \[[@b76], [@b77]\]; the third and fourth domains are responsible for heparin-binding \[[@b77]\], suggesting possible sequestration at interstitial matrix sites (*e.g.* on heparan sulphate proteoglycans); NRP1-binding is mediated mostly through the third, but also the fourth, domain \[[@b77]\] and the fourth domain is responsible for ligand-induced receptor dimerization \[[@b76], [@b78]\], which presumably can facilitate both sVEGFR1-sVEGFR1 homodimerization and sVEGFR1-VEGFR heterodimerization.

Physiological and pathophysiological roles of sVEGFR1
=====================================================

Endogenous sources of sVEGFR1 in human beings include vascular endothelial cells \[[@b40]\], vascular smooth muscle cells \[[@b73]\], activated peripheral blood mononuclear monocytes \[[@b40]\], placental trophoblasts \[[@b40]\], corneal epithelial cells \[[@b79]\] and proximal tubular cells of the renal epithelia \[[@b80]\]. As alluded to, there is evidence for cell type-specific production of sVEGFR1 splice variants: human vascular smooth muscle cells were found to express sFlt1--14 while human endothelial cells expressed the traditional sFlt-1 \[[@b73]\]. This wide assortment of cell types capable of sVEGFR1 expression would suggest its active involvement in multiple physiological and pathological conditions.

Several biological functions of sVEGFR1 have been deduced from its capacity to neutralize VEGF: (1) anti-angiogenesis, by dampening angiogenic VEGF-VEGFR2 signalling \[[@b12], [@b46]\]; (2) anti-oedema, by interfering with VEGF-mediated vascular permeability through VEGFR1 or VEGFR2 \[[@b46], [@b81]\] and (3) anti-inflammation, by attenuating VEGF-VEGFR1-dependent monocyte and macrophage activation and migration \[[@b82]\]. The full extent to which the three potential actions of sVEGFR1 are involved in normal homeostasis is still uncertain. Nonetheless, exogenous administration of sVEGFR1 through gene and protein therapy has already demonstrated efficacy in controlling abnormal angiogenesis, oedema and inflammation in the 17 pre-clinical studies \[[@b12]--[@b15], [@b17]--[@b21], [@b64], [@b81]--[@b86]\] summarized in [Table 1](#tbl1){ref-type="table"}.

###### 

Meta-analysis of 17 pre-clinical studies of the anti-angiogenic, anti-inflammatory and anti-oedema efficacies of sVEGFR1 (sFlt-1) gene/protein therapy *in vivo*

  **Study**                         **Therapy**                       **Vector**                                                                                  **Model**                                              **Disease**                                          **Route of administration**                                                                                **sFlT-1 expression**                                                                              **Effect on VEGF levels**                                **Efficacy**
  --------------------------------- --------------------------------- ------------------------------------------------------------------------------------------- ------------------------------------------------------ ---------------------------------------------------- ---------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------- -------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                                                                  **Cancer**                                                                                                                                                                                                                                                                                                                                                                         
  Kommareddy *et al*. \[[@b12]\]    Gene (sFlt-1)                     nanoparticle encapsulated plasmid DNA (non-viral)                                           orthotopic tumour xenograft in mice                    human breast adeno-carcinoma                         intravenous (systemic); tumour-specific targeting *via* EPR (enhanced permeability and retention) effect   liver and tumour-specific expression; no SkM expression                                            N/A                                                      success: suppression of tumour growth; angiostatic
  Kim *et al*. \[[@b117]\]          Gene (sFlt-1)                     pCMV-sFlt-1 complexed to endothelial cell-targeted polymeric gene carrier (PEI-g-PEG-RGD)   subcutaneous tumour xenograft in mice                  murine colon adeno-carcinoma                         intravenous (systemic); angiogenic endothelium-targeting *via* integrin-binding RGD                        N/A                                                                                                N/A                                                      success: inhibition of tumour growth; longer survival
  Takei *et al*. \[[@b15]\]         Gene (sFlt-1)                     adeno-associated virus                                                                      subcutaneous and peritoneal tumour xenograft in mice   human ovarian serous adeno-carcinoma                 intramuscular (hindlimb skeletal muscle)                                                                   high serum sFlt-1 levels                                                                           lower serum VEGF levels; very high ascitic VEGF level    success: suppressed tumour growth and periotoneal dissemination; angiostatic
  Mahendra *et al*. \[[@b18]\]      Gene (sFlt-1)                     adeno-associated virus                                                                      subcutaneous tumour xenograft in mice                  human ovarian cancer                                 intramuscular (hindlimb quadriceps skeletal muscle)                                                        systemic secretion (inferred?) and expression from muscle; no accumulation in liver                N/A                                                      success: reduced tumour mass and increased tumour-free survival; no hepatotoxicity
  Mahasreshti *et al*. \[[@b20]\]   Gene (sFlt-1)                     adenovirus                                                                                  intraperitoneal tumour xenograft in mice               human ovarian carcinoma                              intravenous (systemic)                                                                                     ∼10x higher plasma sFlt-1 levels than i.p. delivery (Mahareshti); sFlt-1 overexpression in liver   N/A                                                      failure: reduced survival duration; sFlt1-related hepatotoxicity (hemorrhage and necrosis)
  Mahasreshti *et al*. \[[@b21]\]   Gene (sFlt-1)                     adenovirus                                                                                  subcutaneous tumour xenograft in mice                  human ovarian carcinoma                              cancer cells infected with Ad-sFlt-1 *ex vivo* prior to inoculation                                        in situ (inferred) expression of sFlt-1                                                            N/A                                                      success: suppressed tumour growth
  Mahasreshti *et al*. \[[@b21]\]   Gene (sFlt-1)                     adenovirus                                                                                  intraperitoneal tumour xenograft in mice               human ovarian carcinoma                              Intraperitoneal                                                                                            no change in plasma sFlt-1 level *versus* untreated (Mahasreshiti)                                 N/A                                                      success: increased survival duration
  Liu *et al*. \[[@b14]\]           Gene (ECD~1--3~)                  adenovirus                                                                                  subcutaneous tumour xenograft in mice                  human multiple myeloma                               intravenous (systemic)                                                                                     10x higher plasma sFlt-1 levels                                                                    N/A                                                      success: angiostatic suppression of tumour growth
  Gao *et al*. \[[@b13]\]           Gene (sFlt-1)                     adenovirus                                                                                  subcutaneous tumour xenograft in mice                  human tongue carcinoma                               Intratumoral                                                                                               higher serum sFlt-1                                                                                N/A                                                      success: reduced tumour growth and microvessel density
  Zhang *et al*. \[[@b17]\]         Gene (ECD~1--3~)                  adenovirus                                                                                  subcutaneous tumour xenograft in mice                  human colorectal cancer                              Intratumoral                                                                                               increased in tumour                                                                                N/A                                                      success: reduced tumour volume and improved survival
  Sako *et al*. \[[@b83]\]          Gene (sFlt-1)                     adenovirus                                                                                  intraperitoneal tumour xenograft in mice               human gastric cancer                                 intraperitoneal                                                                                            high in peritoneum                                                                                 N/A                                                      success: suppressed periotoneal metastasis of gastric cancer
  Ye *et al*. \[[@b19]\]            Cell-mediated Gene (ECD~1--3~)    embryonic kidney cells transduced with sFlt-1 retroviral vector                             subcutaneous (dorsal flank) tumour xenograft in mice   human follicular thyroid carcinoma                   subcutaneous injection of cells on other dorsal flank                                                      N/A                                                                                                N/A                                                      success: suppressed tumour growth and intratumoral angiogenesis
                                                                                                                                                                  **Ocular neovascularization**                                                                                                                                                                                                                                                                                                                                                      
  Rota *et al*. \[[@b84]\]          Gene (sFlt-1)                     Adenovirus                                                                                  ischemia-induced retinal neovascularization in rats    ischemic retinopathy                                 intravitreous (intraocular)                                                                                intravitreal expression                                                                            N/A                                                      success: inhibition of retinal neovascularization
  Gehlbach *et al*. \[[@b64]\]      Gene (sFlt-1)                     Adenovirus                                                                                  laser-induced choroidal neovascularization in mice     choroidal neovascularization                         intravitreous (intraocular)                                                                                higher in choroid versus retina; none in plasma (Demetriades *et al*.)                             N/A                                                      success: suppressed choroidal neovascularization
  Gehlbach *et al*. \[[@b64]\]      Gene (sFlt-1)                     Adenovirus                                                                                  laser-induced choroidal neovascularization in mice     choroidal neovascularization                         periocular                                                                                                 higher in choroid versus retina; none in plasma (Demetriades *et al*.)                             N/A                                                      success: suppressed choroidal neovascularization
  Gehlbach *et al*. \[[@b64]\]      Gene (sFlt-1)                     Adenovirus                                                                                  oxygen-induced retinal neovascularization in mice      ischemic retinopathy                                 periocular                                                                                                 low in retina (higher versus uninjected); none in plasma (Demetriades *et al*.)                    N/A                                                      success: reduced breakdown of blood-retinal barrier (vascular permeability) but not retinal neovascularization
                                                                                                                                                                  **Inflammation**                                                                                                                                                                                                                                                                                                                                                                   
  Afuwape *et al*. \[[@b85]\]       Gene (sFlt-1)                     Adenovirus                                                                                  collagen-induced arthritis in mice                     rheumatoid arthritis                                 intravenous (systemic)                                                                                     high in liver, synovial tissue and serum                                                           reduced VEGF in ankle joint lysates                      success: suppressed arthritis severity and paw swelling, likely due to reduced synovial neovascularization
  Tsao *et al*. \[[@b82]\]          Protein (sFlt-1-Fc fusion; R&D)   N/A                                                                                         induced endotoxemia and sepsis in mice                 Sepsis                                               intraperitoneal                                                                                            N/A                                                                                                attenuated endotoxemia-induced increase in plasma VEGF   success: anti-inflammatory
  Miotla *et al*. \[[@b86]\]        Protein (sFlt-1-PEG)              N/A                                                                                         collagen-induced arthritis in mice                     rheumatoid arthritis                                 intraperitoneal                                                                                            N/A                                                                                                N/A                                                      success: reduced joint inflammation and bone/cartilage destruction
                                                                                                                                                                  **Vascular permeability**                                                                                                                                                                                                                                                                                                                                                          
  Kumai *et al*. \[[@b81]\]         Gene (sFlt-1)                     adenovirus                                                                                  photochemically induced cerebral ischemia in rats      brain oedema (as a complication of brain ischemia)   intraventricular (lateral ventricle of brain)                                                              sFlt-1 higher in periventricular area, cerebrospinal fluid, but not in serum                       no change in cerebrospinal fluid                         success: reduced infarct volume, brain oedema, blood-brain barrier permeability, monocute/macrophage infiltration; but not angiostatic in ischemic region

Studies ordered by disease type, therapy type, then year. 'ECD1--3'= extracellular domains 1--3 of sFlt-1; 'PEG'= polyethylene glycol-linked.

Of the three putative functions of sVEGFR1 listed above, a great deal of *in vivo* evidence supports an anti-angiogenic role. In normal human physiology, sVEGFR1 was shown to be critical for the maintenance of corneal avascularity needed for optical clarity. Among many anti-angiogenic molecules (angiostatin, endostatin, etc.) present in the cornea, only sVEGFR1 was necessary to suppress the pro-angiogenic effects of local VEGF-A, at least partially through ligand trapping \[[@b69], [@b79]\]. In the setting of human disease, there is increasing evidence that the hypoxia-induced placental production of sVEGFR1 plays a causal role in the pathogenesis of pre-eclampsia. Moreover, a recent animal study suggested a possible role for sVEGFR1 in the blunted angiogenic response in ischemic skeletal muscle in diabetic PAD \[[@b25]\], although this association has yet to be definitively proven in human PAD. While *in vivo* quantification of sVEGFR1 in human studies typically has not distinguished between the splice variants of sVEGFR1, a recent study suggested that they may be responsible for distinct physiological and pathological roles in human beings, *e.g.* that the sFlt1--14, an isoform expressed only in primates, is thought to play an important pathogenic role in human pre-eclampsia \[[@b73]\].

Molecular mechanism of sVEGFR1's anti-angiogenic potential
==========================================================

The precise molecular mechanisms by which sVEGFR1 exerts inhibitory effects on VEGF-dependent signalling are unclear. Nevertheless, two mechanisms have been proposed: (1) direct ligand trapping of VEGF family members (including VEGF-A and PlGF), *i.e.* lowering the effective concentrations of free VEGF available for receptor activation and (2) heterodimerization with surface VEGFRs to form dominant-negative complexes, *i.e.* lowering the effective density of unoccupied VEGFR available for ligand activation \[[@b60], [@b87]\]. More specifically, [Figs 3](#fig03){ref-type="fig"} and [4](#fig04){ref-type="fig"} illustrate how the two mechanisms could affect angiogenic signalling at the endothelial cell surface and in the interstitial matrix, respectively. In this review, we deliberate the effects of sVEGFR1 within the context of sprouting angiogenesis specifically, but because VEGF-A is also involved in the splitting mode of angiogenesis, the inhibitory effects of sVEGFR1 on capillary sprouting will likely carry over to affect splitting angiogenesis as well.

![How sVEGFR1 inhibits angiogenic signalling at the cell surface: two postulated mechanisms. The full set of possible ligand-receptor complexes in the absence of sVEGFR1 is shown in the middle row; those marked with '+' and '--' are thought to transduce pro- and anti-angiogenic signals, respectively. The presence of sVEGFR1 allows new combinations of complexes (top and bottom rows) that do not signal (marked by '0'); these non-signalling species exert anti-angiogenic effects by competing for ligands with pro-angiogenic species. Specifically, in mechanism 1 (top row), sVEGFR1 homodimers (or monomers, not shown) directly compete with surface VEGFRs for ligands (*e.g.* VEGF and PlGF), effectively lowering free ligand concentrations available to bind unoccupied surface VEGFRs. In mechanism 2 (bottom row), sVEGFR1 monomers dimerize with surface VEGFR monomers to form dominant-negative heterodimer complexes, effectively lowering the density of functional surface VEGFRs available to bind free ligands. These two mechanisms are not mutually exclusive and both are likely to occur *in vivo,* although their relative propensities are not known. 'P~1~' and 'P~2~'= placental growth factors-1 and -2; 'V~121~' and 'V~165~'= vascular endothelial growth factor-A (VEGF) isoforms 121 and 165; '1', '2', 'N'= surface receptors VEGFR1, VEGFR2, neuropilin-1; 's1'= soluble VEGFR1.](jcmm0014-0528-f3){#fig03}

![How sVEGFR1 attenuates extracellular VEGF gradients and hinders capillary sprout migration: postulated mechanisms. The interstitial VEGF gradients that endothelial vessel sprouts sense and respond to in migration may consist of: (1) matrix-bound VEGF, (2 a-b) free diffusible VEGF, (3) MMP-cleaved active fragment VEGF~113~ and (4) plasmin-cleaved active fragment VEGF~110~. Theoretically, sVEGFR1 can attenuate VEGF gradients by binding any of these subpopulations: either masking them from endothelial receptor sensing, or protecting matrix-bound VEGF from dissociating or being cleaved into active diffusible forms. 'V~121~'= VEGF isoform 121; 'V~\>121~'= VEGF isoforms 165, 189, 206, etc.; 'MMP'= matrix metalloproteinase; 'GAG'= glycosaminoglycan domains on heparin sulphate proteoglycans (interstitial VEGF-binding sites); 's1'= soluble VEGFR1.](jcmm0014-0528-f4){#fig04}

[Figure 3](#fig03){ref-type="fig"} considers the absolute intensity of VEGF signalling at capillary surfaces -- relevant for activation of angiogenic sprouting -- under the ligand system of PlGF-1, PlGF-2, VEGF~121~ and VEGF~165~. In the absence of sVEGFR1, the membrane-tethered receptors (VEGFR1 and VEGFR2 homodimers; VEGFR1-VEGR2 heterodimers) transduce ligand-specific signals, *e.g.* PlGF activation of VEGFR1 is pro-angiogenic while VEGF-A activation of VEGFR1 is weakly anti-angiogenic \[[@b46]\]. The introduction of sVEGFR1 presents new combinations of receptors that do not signal: diffusible sVEGFR1 acting as a VEGF sink (decoy receptor); and membrane-bound sVEGFR1-VEGFR heterodimers as dominant-negative complexes. Therefore, these non-signalling sVEGFR1 receptor complexes can concurrently exert anti-angiogenic effects at the cell surface by competing with the functional pro-angiogenic receptors for ligands, *e.g.* competing with VEGFR1 for PlGF and competing with VEGFR2 for VEGF-A ([Fig 3](#fig03){ref-type="fig"}). The intrinsic kinase and signalling activities of anti-angiogenic VEGF-VEGFR1 complexes are weaker than those of the pro-angiogenic VEGF-VEGFR2 complexes \[[@b46]\]; hence, the potential pro-angiogenic effects of sVEGFR1 arising from its competition with functional VEGFR1s (effectively reducing inhibitory signalling from VEGF-VEGFR1 compelxes) may be much weaker than its anti-angiogenic effects described above. Also, it appears from these theoretical considerations that the extent of sVEGFR1's anti-angiogenic effects is ligand dependent. sVEGFR1 binding to PlGF is entirely anti-angiogenic, whereas binding to VEGF-A is only partially anti-angiogenic. *Ex vivo* evidence (sVEGFR1 from pooled amniotic fluids) supports sVEGFR1's capacity to act as a direct sink for VEGF and PlGF, but the relative contributions of this molecular mechanism and sVEGFR1 heterodimerization with transmembrane receptors to sVEGFR1's observed anti-angiogenic effects *in vivo*\[[@b59]\] is not known.

[Figure 4](#fig04){ref-type="fig"} considers how the matrix-bound VEGF in the extracellular space -- which shape the interstitial VEGF gradients that guide the migration and branching of sprouting vessels \[[@b46]\]-- may additionally be attenuated by the presence of sVEGFR1. In the absence of sVEGFR1, the VEGF gradients sensed by endothelial tip cell filopodia may comprise freely diffusing VEGF, matrix-bound VEGF and active VEGF fragments (VEGF~110~ and VEGF~113~) released from the matrix by plasmin or matrix metalloproteinase (MMP) cleavage of the larger isoforms of VEGF (VEGF~\>121~). The possibility that sVEGFR1 might bind to matrix-bound VEGF has not been confirmed, but theoretically sVEGFR1 could exert anti-angiogenic effects on capillary sprouts simply by masking matrix-bound VEGF from direct filopodia sensing or by protecting matrix-bound VEGF from plasmin/MMP digestion and activation \[[@b87]\]. *In vitro* evidence supports a critical role for sVEGFR1 in vessel branching \[[@b88]\], but it remains unclear whether this is due to sVEGFR1-mediated attenuation of interstitial gradients or sVEGFR1 heterodimerization with surface VEGFRs.

Computational simulation of these biomolecular interactions provides an important means to decipher the relative contributions of each mechanism to sVEGFR1's anti-angiogenic effects \[[@b89], [@b90]\]. Experimentally, whether dominant-negative heterodimerization plays a significant role *in vivo* may be determined by quantifying the differential anti-angiogenic effects of sVEGFR1 *versus* ECD~1--3~ (the first three extracellular Ig-like domains of VEGFR1), which may not be able to dimerize with surface VEGFR, as the fourth Ig-like domain appears to play a role in receptor dimerization \[[@b76], [@b78]\]. Several studies of ECD~1--3~ gene delivery *in vivo* ([Table 1](#tbl1){ref-type="table"}) and *in vitro* ([Table 2](#tbl2){ref-type="table"}) have demonstrated angiostatic effects in tumour xenografts in mice as well as inhibitory effects on HUVEC proliferation, respectively. These data would suggest that VEGF sequestration alone is sufficient for sVEGFR1's anti-angiogenic effects. However, without a quantitative, controlled comparison of sVEGFR1 *versus* ECD~1--3~ gene therapy, synergistic but redundant anti-angiogenic effects of the surface heterodimerization mechanism cannot be ruled out.

###### 

Meta-analysis of pre-clinical studies of the anti-angiogenic efficacy of sVEGFR1 (sFlt-1) gene/protein therapy *in vitro*

  **Study**                         **Therapy**                      **Vector**                                                            **Model**                                                                        **Disease**   **Route of administration**                                                           **sFlt-1 expression**                            **Effect on VEGF levels**   **Efficacy**
  --------------------------------- -------------------------------- --------------------------------------------------------------------- -------------------------------------------------------------------------------- ------------- ------------------------------------------------------------------------------------- ------------------------------------------------ --------------------------- ------------------------------------------------------------------
  Liu *et al*. \[[@b14]\]           Gene (ECD~1--3~)                 adenovirus                                                            HUVEC (endothelial cells) and KM3 (multiple myeloma cells) proliferation assay   N/A           HUVEC: conditioned media from transfected KM3 cells; KM3: transfected with ADV-sFlt   high in conditioned media *versus* ADV-LacZ      N/A                         success: inhibited HUVEC proliferation but not KM3 proliferation
  Gao *et al*. \[[@b13]\]           Gene (sFlt-1)                    adenovirus                                                            HUVEC (endothelial cells) proliferation assay                                    N/A           conditioned media from transfected ovarian cancer cells                               high in conditioned media *versus* AdGFP         N/A                         success: inhibition of HUVEC proliferation
  Mahendra *et al*. \[[@b18]\]      Gene (sFlt-1)                    adeno-associated virus                                                HUVEC (endothelial cells) proliferation assay                                    N/A           conditioned media from transfected kidney cells                                       high in supernatant *versus* Ad-GFP              N/A                         success: angiostain-comparable inhibition of HUVEC proliferation
  Mahasreshti *et al*. \[[@b21]\]   Gene (sFlt-1)                    adenovirus                                                            HUVEC (endothelial cells) proliferation assay                                    N/A           conditioned media from transfected ovarian cancer cells                               high in supernatant *versus* mock-transduction   N/A                         success: inhibition of HUVEC proliferation
  Ye *et al*. \[[@b19]\]            Cell-mediated Gene (ECD~1--3~)   embryonic kidney cell line transduced with sFlt-1 retroviral vector   HUVEC (endothelial cells) proliferation assay                                    N/A           dual-chamber cell coculture Transwell system                                          N/A                                              N/A                         success: inhibition of HUVEC proliferation

'ECD1--3' = extracellular domains 1--3 of sFlt-1.

sVEGFR1 as a clinical marker for disease
========================================

Since 2000, at least 20 studies \[[@b27], [@b42]--[@b44], [@b61]--[@b63], [@b66], [@b80], [@b91]--[@b101]\] have quantified sVEGFR1 levels in a diverse range of diseases associated with pathological changes of VEGF or PlGF levels, as summarized in [Tables 3](#tbl3){ref-type="table"} to 5. Most measurements in [Tables 3](#tbl3){ref-type="table"}--5 were of circulating (plasma/serum) sVEGFR1, but a few measurements were from urine and tissue (brain) extracts as well.

###### 

Meta-analysis of 20 studies of human VEGF and sVEGFR1 measurements in health and disease: diagnostic / prognostic value

  **Study**                         **Proposed Marker Type**                                                                                                                                                                                                                                                                                                                                                                                           
  --------------------------------- -------------------------- ----------------------------------------------------------------------------------- ------------------------------------- -------------------------------------------------------------------------- --------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------ ---------------------------------------
  Lamszus *et al*. \[[@b91]\]       2003                       malignancy of astrocytic gliomas (*e.g*. glioblastoma = most severe grade)          homogenized tumour / brain extracts   ELISA (Bender MedSystems for sVEGFR1; R&D for VEGF)                        lower sVEGFR1:VEGF                                        more malignant grade                                                                                                     Prognostic
  Bando *et al*. \[[@b61]\]         2005                       primary breast cancer                                                               homogenized tumour extracts           ELISA (Bender MedSystems for sVEGFR1; R&D for free VEGF)                   cut-off: sVEGFR1:(total VEGF) \< 0.5                      poor disease-free (P = 0.008) and overall (P = 0.0002) survival                                                          Prognostic
  Clavel *et al*. \[[@b92]\]        2007                       arthritis (progressive study)                                                       serum                                 ELISA (R&D; sandwich/free for both)                                        serum VEGF and sFlt-1                                     correlated with indices of inflammation and bone destruction                                                             Prognostic
  Chang *et al*. \[[@b93]\]         2008                       pancreatic cancer                                                                   serum                                 ELISA (Quantikine, R&D; sandwich/free for both)                            higher serum VEGF/sVEGFR1                                 poor survival                                                                                                            Prognostic
  Woolcock *et al*. \[[@b42]\]      2008                       pre-eclampsia                                                                       serum                                 ELISA (BD)                                                                 serum cut-off: sFlt-1 \> 1.9 ng/ml                        pre-eclampsia with 94% sensitivity, 78% specificity, 75% positive predictive value                                       Diagnostic
  Diab *et al*. \[[@b43]\]          2008                       pre-eclampsia                                                                       plasma                                ELISA (R&D; capture/free sVEGFR1)                                          plasma cut-off: sFlt-1/PlGF \> 3.92                       pre-eclampsia and intrauterine growth restriction with 98% sensitivity, 95% specificity, 93% positive predictive value   Diagnostic
  Widmer *et al*. \[[@b44]\]        2007                       meta-analysis of pre-eclampsia studies (10 studies of sFlt-1; 14 studies of PlGF)                                                                                                                    3rd-trimester increases in sFlt-1 and decreases in PlGF   pre-eclampsia                                                                                                            Diagnostic
  Aref *et al*. \[[@b66]\]          2005                       Acute myeloid leukaemia                                                             plasma                                ELISA (Quantikine, R&D)                                                    higher plasma VEGF/sFlt-1                                 poor acute myeloid leukaemia outcome (therapy response / survival)                                                       Prognostic
  Bailey *et al*. \[[@b94]\]        2006                       acute exercise                                                                      plasma                                ELISA (R&D; free VEGF)                                                     plasma: transient peak in sVEGFR1 and later dip in VEGF   hypoxia-induction of sVEGFR1?                                                                                            unknown
  Jaroszewicz *et al*. \[[@b62]\]   2008                       liver cirrhosis                                                                     plasma                                ELISA (Chemikine, Chemicon for free VEGF165; Quantikine, R&D for sFlt-1)   plasma VEGF and sVEGFR1                                   associated with indices of hepatic insufficiency                                                                         Prognostic
  Kim *et al*. \[[@b80]\]           2005                       stages of diabetic nephropathy                                                      plasma                                ELISA (Quantikine R&D for free VEGF; ReliaTech GmbH for free sFlt-1)                                                                                                                                                                                          
  Kim *et al*. \[[@b80]\]           2005                                                                                                           urinary                               ELISA (Quantikine R&D for free VEGF; ReliaTech GmbH for free sFlt-1)       increased urinary VEGF and sFlt-1 excretion               diabetic microalbuminuria and proteinuria                                                                                unknown
  Shapiro *et al*. \[[@b63]\]       2008                       sepsis severity (prospective study)                                                 plasma                                ELISA (Quantikine, R&D; free VEGF and sVEGFR1)                             plasma VEGF and sFlt-1                                    correlated with illness severity (noninfected versus infected without shock versus septic shock)                         Diagnostic (prospective) / Prognostic
  Felmeden *et al*. \[[@b95]\]      2003                       hypertension                                                                        plasma                                modified ELISA (R&D)                                                       plasma: higher VEGF; lower sFlt-1                         hypertensive (*versus* control)                                                                                          unknown
  Blann *et al*. \[[@b27]\]         2002                       diabetes with atherosclerosis (DM+A)                                                plasma                                modified ELISA (R&D)                                                       plasma: higher VEGF                                       DM+A (*versus* control)                                                                                                  unknown
  Chung *et al*. \[[@b96]\]         2003                       CAD                                                                                 plasma                                modified ELISA (R&D)                                                       plasma: higher VEGF; lower sFlt-1                         CAD (*versus* control)                                                                                                   unknown
  Lip *et al*. \[[@b97]\]           2000                       proliferative retinopathy                                                           plasma                                modified ELISA (R&D)                                                       plasma VEGF                                               high in disease; low after successful laser treatment                                                                    Prognostic
  Lip *et al*. \[[@b98]\]           2002                       normal tension glaucoma (NTG)                                                       plasma                                modified ELISA (R&D)                                                                                                                                                                                                                                          
  Lip *et al*. \[[@b98]\]           2002                       primary open angle glaucoma (POAG)                                                  plasma                                modified ELISA (R&D)                                                       plasma: higher VEGF; lower sFlt-1                         glaucoma (*versus* control)                                                                                              unknown
  Findley *et al*. \[[@b99]\]       2008                       PAD severity (intermittent claudication, IC *versus* critical limb ischemia, CLI)   plasma                                ELISA (R&D for VEGF~165~ and sFlt-1)                                       plasma VEGF increases                                     correlated with PAD severity: highest in CLI *versus* (IC or healthy)                                                    Prognostic
  Makin *et al*. \[[@b100]\]        2003                       PAD                                                                                 plasma                                ELISA (R&D)                                                                plasma: higher VEGF                                       PAD (*versus* control)                                                                                                   unknown
  Blann *et al*. \[[@b27]\]         2002                       PAD                                                                                 plasma                                modified ELISA (R&D)                                                       plasma: higher VEGF; lower sFlt-1                         PAD (*versus* control)                                                                                                   unknown
  Blann *et al*. \[[@b27]\]         2002                       CAD                                                                                 plasma                                modified ELISA (R&D)                                                       plasma: higher VEGF                                       CAD (*versus* control)                                                                                                   unknown
  Belgore *et al*. \[[@b101]\]      2001                       cardiovascular disease (CVD+PAD)                                                    plasma                                modified ELISA (R&D)                                                       plasma: higher VEGF; lower sFlt-1                         PAD (*versus* control)                                                                                                   unknown

Studies ordered by source and disease/condition, then by measured healthy values of plasma sVEGFR1.

Researchers are increasingly finding clinical utility for sVEGFR1 as a diagnostic (disease identification) and/or prognostic (disease progression) marker in diverse medical conditions, either independently or in combination with VEGF or PlGF ([Table 3](#tbl3){ref-type="table"}). As noted, it is well established that increased circulating sVEGFR1 and reduced free PlGF and free VEGF in the blood are correlated with the pregnancy disorder pre-eclampsia (a disease of endothelial dysfunction and impaired angiogenesis) compared to normal pregnancies \[[@b41], [@b44], [@b45]\]. Quantitative metrics have shown predictive value for sVEGFR1 in differentiating pre-eclampsia among suspected pregnancies \[[@b42], [@b43]\]. Conversely, among cancers (diseases of unconstrained angiogenesis), including astrocytic gliomas, primary breast cancer, pancreatic cancer and acute myeloid leukaemia, low sVEGFR1 to VEGF ratios in tumour extracts, serum or plasma correlated with higher malignancy grades of tumours, poorer patient survival or weaker responsiveness to therapy \[[@b61], [@b66], [@b91], [@b93]\]. In liver cirrhosis (an inflammatory disease of pro-angiogenic status), increases in plasma VEGF and sVEGFR1 were associated with a degree of hepatic insufficiency \[[@b62]\]. In suspected sepsis (systemic inflammation induced by infection), plasma sVEGFR1 and VEGF have shown potential for predicting illness severity or septic shock \[[@b63]\], where the changes in sVEGFR1 are thought to reflect a compensatory protective response to the VEGF-dependent inflammation \[[@b63], [@b102], [@b103]\]. In PAD -- where skeletal muscle ischemia resulting from atherosclerotic occlusive arterial disease is accompanied by impaired arteriogenesis (the growth of arteriolar collaterals) around the primary occlusive site and impaired angiogenesis in the ischemic muscle downstream of the occlusion \[[@b23]\]-- there is general consensus that plasma VEGF levels are increased relative to healthy controls \[[@b27], [@b27], [@b99], [@b101]\]. Although reported magnitudes of increased VEGF differ among studies, this may reflect differences in PAD severity among patient cohorts, as one study further correlated the plasma VEGF~165~ concentrations with PAD severity (*i.e.* higher in patients with critical limb ischemia than in those with intermittent claudication) \[[@b99]\]. However, there is contradictory evidence regarding whether plasma sVEGFR1 levels are changed in PAD patients relative to healthy controls. Blann *et al*. and Belgore *et al*. documented significantly lower levels of sVEGFR1 \[[@b27], [@b101]\], while Findley *et al*. and Makin *et al*. observed no significant differences \[[@b99], [@b100]\]. Hence the potential use of plasma sVEGFR1 as a marker for disease severity in PAD remains controversial.

Plasma VEGF and sVEGFR1: non-uniform predictors of angiogenic status across all diseases
========================================================================================

While the studies described above have reported successful design of diagnostic/prognostic metrics for individual diseases or for severity of a given disease using combined measures of VEGF and sVEGFR1, a meta-analysis of 14 studies suggests that the plasma levels of these two angiogenic markers still do not adequately serve as reliable universal predictors of the overall angiogenic status across all angiogenesis-dependent diseases, as explained further below.

The 14 studies used in the meta-analysis ([Fig. 5](#fig05){ref-type="fig"}) included every study in [Tables 3](#tbl3){ref-type="table"}--5 that measured VEGF and/or sVEGFR1 specifically in plasma, *i.e.* excluding measurements from tissue homogenates, serum and urine for a consistent sampling source. The 14 studies are grouped according to disease type and angiogenic status: those marked by '+' are diseases/conditions in which angiogenesis is up-regulated; 'i' further identifies angiogenic states that overlap with inflammatory states; those marked by '--' are diseases of insufficient or impaired angiogenesis; those marked '±' are atherosclerotic vascular diseases, in which angiogenesis fuels the growth of primary atherosclerotic plaques at obstructed blood vessels, but impaired angiogenesis (in addition to insufficient arteriogenesis) fails to provide sufficient oxygen delivery to the ischemic muscle tissues downstream of the obstructive site.

![Summary of 14 studies of plasma VEGF and sVEGFR1 measurements in health and disease. Studies are labelled as '\[First Author\] (Year) \[Disease/Condition of Study\]\[Status\]', where status = {+, excessive angiogenesis; --, insufficient angiogenesis; i, inflammatory; ±, atherosclerotic vascular disease, with angiogenesis at primary atherosclerotic plaques, and insufficient angiogenesis in ischemic muscle}. Data values are shown for healthy control bars; percentage changes relative to healthy controls are shown for disease/condition bars. In general, diseases of apparently opposing angiogenic status (*e.g.* ocular neovascularization *versus* cardiac ischemia) showed similar increases in plasma VEGF (A) and decreases in plasma concentration ratios of sVEGFR1:VEGF (C); while diseases of seemingly similar angiogenic status (*e.g.* glaucoma *versus* proliferative retinopathy) showed inconsistent changes in plasma sVEGFR1 (B). Error bars not shown due to inter-study variation in measures chosen (S.D. = standard deviation, S.E.M. = standard error in the mean, IQR = interquartile range). See [Tables 4](#tbl4){ref-type="table"} and [5](#tbl5){ref-type="table"} for raw data.](jcmm0014-0528-f5){#fig05}

###### 

Meta-analysis of 20 studies of human VEGF and sVEGFR1 measurements in health and disease: healthy controls

  **Study**                         **Healthy Control**   **VEGF**   **sVEGFR1**                                                                                               
  --------------------------------- --------------------- ---------- ----------------------- -------- --------- --------- ------------------- --------- --------- ------------ -------------------
  Lamszus *et al*. \[[@b91]\]       2003                  5          Healthy white matter    0.06     ±S.D.     0.1       ng/mg               0         ±S.D.     0            ng/mg
  Bando *et al*. \[[@b61]\]         2005                  N/A                                N/A                                              N/A                              
  Clavel *et al*. \[[@b92]\]        2007                  N/A                                N/A                                              N/A                              
  Chang *et al*. \[[@b93]\]         2008                  60         Healthy                 187.63   ±S.D.     393.32    pg/ml               0.01555   ±S.D.     0.00198      ng/ml
  Woolcock *et al*. \[[@b42]\]      2008                  18         Normotensive women      N/A                                              0.47      IQR       0.11--0.89   ng/ml
  Diab *et al*. \[[@b43]\]          2008                  66         Normal pregnant women   N/A                                              0.5133    ±S.D.     0.0726       ng/ml
  Widmer *et al*. \[[@b44]\]        2007                  N/A                                N/A                                              N/A                              
  Aref *et al*. \[[@b66]\]          2005                  10         Healthy                 138      ±S.E.M.   4.7       pg/ml               0.0225    ±S.E.M.   0.0009       ng/ml
  Bailey *et al*. \[[@b94]\]        2006                  5          Healthy @ basal         37.3     ±S.E.     7.7       pg/ml               0.0488    ±S.E.     0.009        ng/ml
  Jaroszewicz *et al*. \[[@b62]\]   2008                  15         Healthy                 46.8     ±S.E.M.   4.1       pg/ml               0.1051    ±S.E.M.   0.0059       ng/ml
  Kim *et al*. \[[@b80]\]           2005                  47         Healthy                 14.3     IQR       48        pg/ml               0.11      IQR       0.25         ng/ml
  Kim *et al*. \[[@b80]\]           2005                  47         Healthy                 27.8     IQR       49        pg/ mg creatinine   0.05      IQR       0.21         ng/ mg creatinine
  Shapiro *et al*. \[[@b63]\]       2008                  66         Noninfected             580      ±S.D.     380       pg/ml               1.59      ±S.D.     0.79         ng/ml
  Felmeden *et al*. \[[@b95]\]      2003                  60         Normotensive healthy    125      IQR       40--213   pg/ml               17        IQR       10--33       ng/ml
  Blann *et al*. \[[@b27]\]         2002                  14         Healthy                 92.5     IQR       20--175   pg/ml               20        IQR       3--32        ng/ml
  Chung *et al*. \[[@b96]\]         2003                  34         Healthy                 80       IQR       20--176   pg/ml               20        IQR       9--40        ng/ml
  Lip *et al*. \[[@b97]\]           2000                  18         Healthy                 50       IQR       16--113   pg/ml               20        IQR       9.6--26      ng/ml
  Lip *et al*. \[[@b98]\]           2002                  26         Healthy                 83       IQR       13--125   pg/ml               28        IQR       18--39       ng/ml
  Findley *et al*. \[[@b99]\]       2008                  23         Healthy                 50       ±S.D.     30        pg/ml               0.9       ±S.D.     0.4          ng/ml
  Makin *et al*. \[[@b100]\]        2003                  50         Healthy                 78       IQR       69--100   pg/ml               0.9       IQR       0.2--2.9     ng/ml
  Blann *et al*. \[[@b27]\]         2002                  70         Healthy                 77.5     IQR       20--149   pg/ml               22        IQR       14--37       ng/ml
  Belgore *et al*. \[[@b101]\]      2001                  40         Healthy                 113      IQR       33--231   pg/ml               21        IQR       10--78       ng/ml

Studies ordered by source and disease/condition, then by measured healthy values of plasma sVEGFR1. S.D. = standard deviation, S.E.M. = standard error in the mean, IQR = interquartile range.

###### 

Meta-analysis of 20 studies of human VEGF and sVEGFR1 measurements in health and disease: disease/condition

  **Study**                         **Disease/Condition**   **VEGF**   **sVEGFR1**                                                                                                                         
  --------------------------------- ----------------------- ---------- ------------------------------------ ------- --------- -------------- -------------------------- --------- --------- -------------- --------------------------
  Lamszus *et al*. \[[@b91]\]       2003                    46         glioblastomas                        11.9    ±S.D.     20.74          ng/mg protein              3.26      ±S.D.     4              ng/mg protein
  Bando *et al*. \[[@b61]\]         2005                    202        all primary breast cancers           0.532   95% CI    0.432--0.632   ng total VEGF/mg protein   0.949     95% CI    0.849--1.048   ng/mg protein
  Clavel *et al*. \[[@b92]\]        2007                    310        early arthritis @ baseline           465     ±S.D.     270            pg/ml                      0.035     ±S.D.     0.03           ng/ml
  Clavel *et al*. \[[@b92]\]        2007                    310        early arthritis @ 1 yr               1212    ±S.D.     1041           pg/ml                      0.095     ±S.D.     0.073          ng/ml
  Chang *et al*. \[[@b93]\]         2008                    92         pancreatic cancer                    538.8   ±S.D.     559.5          pg/ml                      0.05094   ±S.D.     0.05117        ng/ml
  Woolcock *et al*. \[[@b42]\]      2008                    18         pre-eclampsia                        N/A                                                         3.13      IQR       2.14--4.17     ng/ml
  Diab *et al*. \[[@b43]\]          2008                    8          early onset pre-eclampsia            N/A                                                         2.562     ±S.D.     1.611          ng/ml
  Widmer *et al*. \[[@b44]\]        2007                                                                                                                                                                   
  Aref *et al*. \[[@b66]\]          2005                    43         Acute myeloid leukaemia              373.9   ±S.E.M.   34             pg/ml                      0.0497    ±S.E.M.   0.0028         ng/ml
  Bailey *et al*. \[[@b94]\]        2006                    5          healthy @ peak change                17.5    ±S.E.     2.5            pg/ml @ 2 hrs post-ex.     0.0729    ±S.E.     0.0146         ng/ml @ 0.5 hrs post-ex.
  Jaroszewicz *et al*. \[[@b62]\]   2008                    78         liver cirrhosis of diff types        153.1   ±S.E.M.   51.9           pg/ml                      0.2798    ±S.E.M.   0.0344         ng/ml
  Kim *et al*. \[[@b80]\]           2005                    33         proteinuria                          14.2    IQR       23.3           pg/ml                      0.2       IQR       0.24           ng/ml
  Kim *et al*. \[[@b80]\]           2005                    33         proteinuria                          245     IQR       1048.4         pg/mg creatinine           0.18      IQR       0.25           ng/mg creatinine
  Shapiro *et al*. \[[@b63]\]       2008                    17         suspected infection + septic shock   1660    ±S.D.     1710           pg/ml                      5.51      ±S.D.     3.71           ng/ml
  Felmeden *et al*. \[[@b95]\]      2003                    234        hypertensive                         340     IQR       190--1300      pg/ml                      4.3       IQR       1.5--14.0      ng/ml
  Blann *et al*. \[[@b27]\]         2002                    14         DM+A                                 755     IQR       100--1975      pg/ml                      32        IQR       17--125        ng/ml
  Chung *et al*. \[[@b96]\]         2003                    111        CAD                                  130     IQR       100--250       pg/ml                      7.5       IQR       1.9--19        ng/ml
  Lip *et al*. \[[@b97]\]           2000                    18         proliferative retinopathy            350     IQR       200--581       pg/ml                      22.5      IQR       17.5--37.5     ng/ml
  Lip *et al*. \[[@b98]\]           2002                    26         NTG                                  225     IQR       110---500      pg/ml                      17        IQR       6--60          ng/ml
  Lip *et al*. \[[@b98]\]                                   24         POAG                                 150     IQR       118--235       pg/ml                      6         IQR       2--19          ng/ml
  Findley *et al*. \[[@b99]\]       2008                    46         PAD (IC+CLI)                         80      ±S.D.     60             pg/ml                      0.8       ±S.D.     0.25           ng/ml
  Findley *et al*. \[[@b99]\]                               23         IC                                   60      ±S.D.     30             pg/ml                      N/A                                
  Findley *et al*. \[[@b99]\]                               23         CLI                                  110     ±S.D.     70             pg/ml                      N/A                                
  Makin *et al*. \[[@b100]\]        2003                    234        PAD                                  100     IQR       80--160        pg/ml                      1         IQR       0.5--4.0       ng/ml
  Blann *et al*. \[[@b27]\]         2002                    70         PAD                                  395     IQR       187--912       pg/ml                      6         IQR       1--26          ng/ml
  Blann *et al*. \[[@b27]\]                                 70         CAD                                  400     IQR       139--1404      pg/ml                      15        IQR       1--63          ng/ml
  Belgore *et al*. \[[@b101]\]      2001                    40         CVD(+PAD)                            403     IQR       158--925       pg/ml                      8         IQR       2--22          ng/ml

Studies ordered by source and disease/condition, then by measured healthy values of plasma sVEGFR1. S.D. = standard deviation, S.E.M. = standard error in the mean, IQR = interquartile range.

Firstly, plasma VEGF is elevated in almost all diseases/conditions ([Fig. 5A](#fig05){ref-type="fig"}), including the neoplastic diseases (acute myeloid leukaemia), diseases of abnormal ocular neovascularizations (retinopathy, glaucoma), inflammatory diseases (cirrhosis, sepsis) and diseases of cardiac and peripheral ischemia (CAD, PAD). Thus plasma VEGF alone cannot serve as a differential marker for angiogenic status. Secondly, there is not a consistent trend in plasma sVEGFR1 level changes within the diseases of supposedly similar angiogenic status ([Fig. 5B](#fig05){ref-type="fig"}). For example, among the diseases of aberrant ocular neovascularization, plasma sVEGFR1 decreased in the glaucomas but increased in proliferative retinopathy; among the atherosclerotic vascular diseases, plasma sVEGFR1 increased in atherosclerotic diabetes, but decreased in CAD and sometimes in PAD. Thirdly, neither can the pathological changes in plasma sVEGFR1:VEGF concentration ratios be used to differentiate between diseases of supposedly opposing angiogenic status ([Fig. 5C](#fig05){ref-type="fig"}). Thus, the simultaneous measurement of circulating VEGF and sVEGFR1 -- a major VEGF neutralizing agent -- in attempt to quantify the actual bioavailability of circulating VEGF, still does not uniformly predict the angiogenic status across the diseases examined here.

Systems biology perspective: unifying interpretation of plasma angiogenic markers
=================================================================================

This section examines potential flaws and pitfalls in relying on just two markers in isolation -- the plasma VEGF and sVEGFR1 levels -- to encapsulate the angiogenic status of angiogenesis-dependent diseases. We also propose that a more integrative systems biology perspective \[[@b104], [@b105]\] can benefit the interpretation of these markers to aid prediction of the angiogenic status across a diversity of physiological and pathophysiological conditions.

1.Baseline heterogeneity in clinical measurements of healthy VEGF and sVEGFR1 levels in plasma
----------------------------------------------------------------------------------------------

The quantitative variability in published measurements of circulating VEGF is well documented and can span up to three orders of magnitude due to inter-study differences in assay protocols \[[@b106], [@b107]\]. Similarly, inter-study heterogeneity in measurements of circulating sVEGFR1 was reported in a meta-analysis of 10 studies examining normal pregnancies *versus* pre-eclampsia \[[@b44]\]. Having normalized the sample sources in [Fig. 5](#fig05){ref-type="fig"} to consider only plasma measurements, healthy VEGF levels still varied over an order of magnitude from 14.3 pg/ml to 580 pg/ml, while healthy sVEGFR1 levels varied by three orders of magnitude from 22.5 pg/ml to 28 ng/ml. This striking data variability may be attributable to inter-study methodological differences, such as in the definition of inclusion/exclusion criteria of healthy cohorts, or in the sampling, preparation and analysis of blood protein concentrations. In particular, the healthy measurements of sVEGFR1 can be divided into two extreme ranges ([Fig. 5](#fig05){ref-type="fig"}), with one set well below 2 ng/ml and the other above 15 ng/ml; it is uncertain whether the systematically higher values reported in the latter dataset \[[@b27], [@b95]--[@b98], [@b101]\] could be accounted for by the in-house modified ELISA protocols commonly used in those studies ([Table 3](#tbl3){ref-type="table"}). Methodological disparities aside, natural variation of the physiological baseline could account for the wide intra-study ranges observed among individuals within control groups \[[@b27], [@b44]\]. Of particular concern in analysing levels of these proteins, in multiple instances the inter-study differences between 'healthy' baseline values often exceed in magnitude the intra-study differences between 'healthy' and 'disease/condition' values, especially for sVEGFR1 ([Fig. 5](#fig05){ref-type="fig"}). Thus, a standardization of assay protocols and calibrants for the clinical measurement of circulating VEGF and sVEGFR1 is imperative. If the variability of healthy baseline measurements does in fact reflect natural physiological variation, the significance and the diagnostic/prognostic utility of the pathological changes in plasma levels of VEGF and sVEGFR1 as shown in [Fig. 5](#fig05){ref-type="fig"} would be questionable.

2.Effect of sVEGFR1 on VEGF bioavailability: VEGF-sVEGFR1 complexes
-------------------------------------------------------------------

The rationale behind using VEGF:sVEGFR1 ratios as indicators of angiogenic status \[[@b61], [@b93]\] is based on an assumption that sVEGFR1 is the predominant regulator of circulating VEGF bioavailability, other than the intrinsic VEGF production rates. This assumption has yet to be validated, in light of mounting evidence of other potential blood carriers of VEGF: soluble VEGFR2 \[[@b65], [@b66]\], soluble NRP1 \[[@b67], [@b68]\], plasma fibronectin \[[@b53], [@b108]--[@b111]\] and platelets \[[@b112]\]. Furthermore, sVEGFR1 itself has additional ligand partners in addition to VEGF-A, as it also binds VEGF-B and placental growth factor (PlGF) \[[@b87], [@b113]\]. In order to assess how much of the bound/unavailable circulating VEGF is sVEGFR1-complexed and vice versa, simultaneous quantifications are necessary for free VEGF (capture/sandwich immunoassays \[[@b106]\]), free sVEGFR1, total VEGF (competitive immunoassays \[[@b106]\]), total sVEGFR1 and VEGF-sVEGFR1 complexes (*e.g.* the specific modified assay developed by Belgore *et al.*\[[@b101]\]). In the 'Assay' column in [Table 3](#tbl3){ref-type="table"}, we note where free VEGF and sVEGFR1 were measured; in other cases the authors did not specify whether the measurement was for free or total species. In future experimental studies, this distinction should be carefully addressed in the design and reporting of experimental methodology. Crucially, experiments are needed to specifically determine whether a given ELISA will distinguish between bound and unbound proteins, *i.e.* whether individual antibodies detect epitopes that are masked after binding. In fact, differences in ELISA specificity may account for the observed marked differences in levels of circulating VEGF and sVEGFR1. Without direct quantifications of circulating VEGF-sVEGFR1 complexes, it would be nearly impossible to decipher, for example, how much of a pathological increase in available free VEGF is due to: increased VEGF production rate, increased VEGF-sVEGFR1 complex dissociation, or altered VEGF-binding to other carrier proteins.

3.Compartmental analysis: biotransport and biodistribution
----------------------------------------------------------

VEGF and sVEGFR1 are soluble proteins subjected to pharmacokinetic transport between organ and tissue compartments (*e.g.* due to vascular permeability and lymphatic drainage). As such, their plasma concentrations do not necessarily reflect their interstitial concentrations within organs/tissues where the local angiogenic status is of interest with respect to the disease under consideration. This may be the case in PAD, in which two human studies have documented increased sVEGFR1 in the plasma ([Fig. 5](#fig05){ref-type="fig"}), yet in a diabetic mouse model of PAD, muscle expression of sVEGFR1 increased after surgically induced hindlimb ischemia \[[@b25]\]. To the best of our knowledge, there are currently no available data assessing interstitial levels of sVEGFR1 in human beings. Interstitial VEGF has been measured by microdialysis \[[@b114], [@b115]\], but technical concerns have been raised regarding the accuracy in using high molecular-weight cut-off microdialysis membranes to study macromolecules such as proteins, including unwanted ultrafiltration that could alter interstitial space compositions \[[@b116]\]. In the case that interstitial sVEGFR1 is truly elevated in PAD patients relative to healthy controls, in contrast to the unchanged/lowered sVEGFR1 levels observed in plasma, one explanation is that biotransport and biodistribution of sVEGFR1 are altered in PAD, *e.g.* lowered lymphatic drainage might lead to accumulation of sVEGFR1 within ischemic tissues. Therefore, in diseases in which the angiogenic markers in plasma seem to predict an angiogenic status other than that expected for the disease, the disparity may be corrected by examining the actual interstitial concentrations of these markers in the diseased compartments.

4.Pathogenic phenomenon *versus* compensatory response
------------------------------------------------------

Even in the case that plasma levels of circulating VEGF and sVEGFR1 accurately reflect the interstitial levels within diseased tissues, it is difficult to discern whether static (single time-point) blood samples reflect pathogenic phenomena or compensatory responses. For instance, in the case of cancer, elevated plasma VEGF ([Fig. 5](#fig05){ref-type="fig"}) typically represents a pathogenic process in which tumour hypoxia induces increased VEGF expression, thereby stimulating excessive angiogenesis in the diseased tissue. On the other hand, in atherosclerotic vascular diseases, the elevated plasma VEGF ([Fig. 5](#fig05){ref-type="fig"}) may be a result of compensatory VEGF up-regulation in response to ineffective angiogenesis at the ischemic muscle tissues or, as in tumours, a pathogenic increase in VEGF that stimulates the growth of the atherosclerotic plaque \[[@b26]\]. In fact, it is known that both VEGF and (s)VEGFR1 expression are hypoxia-inducible due to the presence of a hypoxia response element (HRE) in their gene promoter regions \[[@b87]\]; thus it is plausible that expression of VEGF and sVEGFR1 is up-regulated in both cancer and ischemic disease. In other words, what is different between these diseases may be in the tissue responsiveness to ligand availability -- excessive in cancer and deficient in ischemic diseases, as illustrated in [Fig. 6](#fig06){ref-type="fig"}. Therefore a more complex 'systems biology' interpretation of the plasma levels of VEGF and sVEGFR1 (the inputs) -- one that considers downstream ligand-receptor interactions and signalling cascades (represented as black boxes in [Fig. 6](#fig06){ref-type="fig"}) -- would be needed to predict the angiogenic status (the output) across these different disease states.

![Systems interpretation of circulating markers and angiogenic status. Both VEGF and sVEGFR1 have a HRE in their gene promoters, which is at least partly responsible for the up-regulated expression of both in response to hypoxia (*e.g.* in cancer) or ischemia (*e.g.* in atherosclerotic vascular diseases). It is uncertain how transfer functions (black boxes) transduce similar inputs into different outputs (angiogenic status; circulating markers) in different diseases. The transfer functions for the angiogenic status likely involve complex receptor expression/interactions and intracellular signalling processes. The transfer functions for the circulating markers likely include complex biotransport processes involving contributions from other tissue compartments. Whether circulating levels of VEGF and sVEGFR1 can serve as reliable surrogate markers of angiogenic status at the disease sites depends on the correlation between their respective transfer functions.](jcmm0014-0528-f6){#fig06}

Concluding remarks
==================

Taken together, these necessary distinctions suggest that a systems biology model could provide important insights into the use of plasma VEGF and sVEGFR1 levels as surrogate markers of disease status for a variety of angiogenesis-dependent diseases. To generate such a mathematical model, further experimental data are needed to inform model extensions and model parameterizations: (1) standardization of methodological protocols and definition of healthy baseline ranges of circulating VEGF and sVEGFR1 under normal physiological fluctuations is needed to constrain their healthy 'setpoints' for model predictions; (2) quantification for the plasma concentrations and binding kinetics of all competing blood carriers, including sVEGFR1, is needed to accurately predict the bioavailability of circulating free VEGF; (3) real-time tracking of the biotransport processes (vascular permeability rates, lymphatic drainage rates, etc.) and systemic distributions (interstitial, intracellular and intravascular densities in various tissues) of VEGF and sVEGFR1 will help elucidate the relationship between protein measurements from varying body compartments; and (4) identification and model representation of all molecular components involved in the signal transduction networks of the VEGF system, including feedback loops (*e.g.* receptor expression levels as dependent on ligand activation and auto-phosphorylation), is crucial for discerning between pathogenic and compensatory responses in interpreting the correlation between concentrations of suspected protein markers and a particular disease status.
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